USD10
Actions RPRX
À propos de Royalty PharmaRoyalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
USD10
Actions RPRX
À propos de Royalty PharmaRoyalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Statistiques
FENÊTRE DE TRADING
Ouvert
FERME À
20:00 UTC+0
Capitalisation boursière
19,29 Md $US
PRIX D'OUVERTURE
45,77 $US
BAS (1 an)
29,66 $US
ÉLEVÉ (1 an)
44,93 $US
BAS (24 h)
44,73 $US